Jennifer Farrior

Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial

Sinéad Delany‐Moretlwe, James P. Hughes, Peter Bock et al. · The Lancet · 2022 · 540 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +13

Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities

Myron S. Cohen, Ajay Nirula, Mark J. Mulligan et al. · JAMA · 2021 · 208 citations · Full text

Medicine, Infectious Diseases, Preventive Medicine +10

Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084

Susan H. Eshleman, Jessica M. Fogel, Estelle Piwowar‐Manning et al. · The Journal of Infectious Diseases · 2021 · 69 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Acceptability of a long‐acting injectable HIV prevention product among US and African women: findings from a phase 2 clinical Trial (HPTN 076)

Elizabeth E. Tolley, Sue Li, Sahar Z. Zangeneh et al. · Journal of the International AIDS Society · 2019 · 61 citations · Full text

Public Health, Preventive Medicine, Contraception +14

Clinician Practices and Attitudes Regarding Early Antiretroviral Therapy in the United States

Ann Kurth, Kenneth H. Mayer, Geetha Beauchamp et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2012 · 28 citations

Public Health, Infectious Disease Control, Disease Prevention +14